Evaluation, Laboratory tests and follow-up
Tumor
DISEASE, TUMOR
Tumor assessment will be carried out according to RECIST v1.1 criteria using total body CT scan performed every 8 weeks until progression, at end of vaccination visit, and at end of atezolizumab plus bevacizumab treatment visit. If progressive disease, it could be confirmed by another total body CT scan 4 to 8 weeks after the precedent. A liver MRI will be also planned at baseline, at W9, and at M6. Radiological assessments will be anonymized by the investigational centers and all imaging data will be collected at the end of the study for centralized review.A health-related Qol EORTC-QLQ-C30 questionnaire will be collected at baseline, every 8 weeks until end of treatment visit, at end of vaccination visit, and at end of atezolizumab plus bevacizumab treatment visit.Immunological safety assessment will be performed at baseline, W5 and W9 to analyse IgG, IgE, circulating antibodies (ANA, TPO), cytokine release and anti-drugs-antibodies.